Innate Immune Evasion by Human Respiratory RNA Viruses

Marjolein Kikkert, Marjolein Kikkert

Abstract

The impact of respiratory virus infections on the health of children and adults can be very significant. Yet, in contrast to most other childhood infections as well as other viral and bacterial diseases, prophylactic vaccines or effective antiviral treatments against viral respiratory infections are either still not available, or provide only limited protection. Given the widespread prevalence, a general lack of natural sterilizing immunity, and/or high morbidity and lethality rates of diseases caused by influenza, respiratory syncytial virus, coronaviruses, and rhinoviruses, this difficult situation is a genuine societal challenge. A thorough understanding of the virus-host interactions during these respiratory infections will most probably be pivotal to ultimately meet these challenges. This review attempts to provide a comparative overview of the knowledge about an important part of the interaction between respiratory viruses and their host: the arms race between host innate immunity and viral innate immune evasion. Many, if not all, viruses, including the respiratory viruses listed above, suppress innate immune responses to gain a window of opportunity for efficient virus replication and setting-up of the infection. The consequences for the host's immune response are that it is often incomplete, delayed or diminished, or displays overly strong induction (after the delay) that may cause tissue damage. The affected innate immune response also impacts subsequent adaptive responses, and therefore viral innate immune evasion often undermines fully protective immunity. In this review, innate immune responses relevant for respiratory viruses with an RNA genome will briefly be summarized, and viral innate immune evasion based on shielding viral RNA species away from cellular innate immune sensors will be discussed from different angles. Subsequently, viral enzymatic activities that suppress innate immune responses will be discussed, including activities causing host shut-off and manipulation of stress granule formation. Furthermore, viral protease-mediated immune evasion and viral manipulation of the ubiquitin system will be addressed. Finally, perspectives for use of the reviewed knowledge for the development of novel antiviral strategies will be sketched.

Keywords: 2’O-methylation; Coronavirus; Endoribonuclease; Guanylate-binding proteins; HRV; IAV; Interferon; Replication organelles; Respiratory syncytial virus; Vaccine.

Conflict of interest statement

The author declares no conflicts of interest.

© 2019 The Author(s) Published by S. Karger AG, Basel.

Figures

Fig. 1
Fig. 1
Overview of respiratory viruses and major immune evasive activities as discussed in this review. The location in the viral genomes where immune evasive activities are encoded are indicated with colored spheres. If an activity was allocated to a virus, but the location on the genome is not known, the colored sphere was placed beside the name of the virus. Representations of viral genomes were adapted from ViralZone: www.expasy.org/viralzone, SIB Swiss Institute of Bioinformatics under the Creative Commons License. CoV, coronavirus; RSV, respiratory syncytial virus; ROs, replication organelles.

References

    1. Martin TR, Frevert CW. Innate immunity in the lungs. Proc Am Thorac Soc. 2005;2((5)):403–11.
    1. Gasteiger G, D'Osualdo A, Schubert DA, Weber A, Bruscia EM, Hartl D. Cellular Innate Immunity: An Old Game with New Players. J Innate Immun. 2017;9((2)):111–25.
    1. Zhou JH, Wang YN, Chang QY, Ma P, Hu Y, Cao X. Type III Interferons in Viral Infection and Antiviral Immunity. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology. 2018;51:173–185.
    1. Zhang S, Carriere J, Lin X, Xie N, Feng P. Interplay between Cellular Metabolism and Cytokine Responses during Viral Infection. Viruses. 2018 Sep;10((10)):10.
    1. Wells AI, Coyne CB. Type III Interferons in Antiviral Defenses at Barrier Surfaces. Trends Immunol. 2018 Oct;39((10)):848–58.
    1. Trottein F, Paget C. Natural Killer T Cells and Mucosal-Associated Invariant T Cells in Lung Infections. Front Immunol. 2018 Aug;9:1750.
    1. Supramaniam A, Lui H, Bellette BM, Rudd PA, Herrero LJ. How myeloid cells contribute to the pathogenesis of prominent emerging zoonotic diseases. J Gen Virol. 2018 Aug;99((8)):953–69.
    1. Said EA, Tremblay N, Al-Balushi MS, Al-Jabri AA, Lamarre D. Viruses Seen by Our Cells: The Role of Viral RNA Sensors. J Immunol Res. 2018 Apr;2018:9480497.
    1. Rusek P, Wala M, Druszczyńska M, Fol M. Infectious Agents as Stimuli of Trained Innate Immunity. Int J Mol Sci. 2018 Feb;19((2)):19.
    1. Naumenko V, Turk M, Jenne CN, Kim SJ. Neutrophils in viral infection. Cell Tissue Res. 2018 Mar;371((3)):505–16.
    1. Meier-Stephenson V, Mrozowich T, Pham M, Patel TR. DEAD-box helicases: the Yin and Yang roles in viral infections. Biotechnol Genet Eng Rev. 2018 Apr;34((1)):3–32.
    1. Hammer Q, Rückert T, Romagnani C. Natural killer cell specificity for viral infections. Nat Immunol. 2018 Aug;19((8)):800–8.
    1. Okamoto M, Tsukamoto H, Kouwaki T, Seya T, Oshiumi H. Recognition of Viral RNA by Pattern Recognition Receptors in the Induction of Innate Immunity and Excessive Inflammation During Respiratory Viral Infections. Viral Immunol. 2017 Jul-Aug;30((6)):408–20.
    1. Lambert L, Culley FJ. Innate Immunity to Respiratory Infection in Early Life. Front Immunol. 2017 Nov;8:1570.
    1. Hu MM, Shu HB. Multifaceted roles of TRIM38 in innate immune and inflammatory responses. Cell Mol Immunol. 2017 Apr;14((4)):331–8.
    1. Dagenais-Lussier X, Loucif H, Murira A, Laulhé X, Stäger S, Lamarre A, et al. Sustained IFN-I Expression during Established Persistent Viral Infection: A “Bad Seed” for Protective Immunity. Viruses. 2017 Dec;10((1)):10.
    1. Zinzula L, Tramontano E. Strategies of highly pathogenic RNA viruses to block dsRNA detection by RIG-I-like receptors: hide, mask, hit. Antiviral Res. 2013 Dec;100((3)):615–35.
    1. Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, et al. Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet. 2015 Jan;385((9966)):430–40.
    1. Walker CL, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, et al. Global burden of childhood pneumonia and diarrhoea. Lancet. 2013 Apr;381((9875)):1405–16.
    1. Lambert L, Sagfors AM, Openshaw PJ, Culley FJ. Immunity to RSV in Early-Life. Front Immunol. 2014 Sep;5:466.
    1. Davis ME, Gack MU. Ubiquitination in the antiviral immune response. Virology. 2015 May;479-480:52–65.
    1. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003 Jan;4((1)):69–77.
    1. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003 Jan;4((1)):63–8.
    1. Andreakos E, Salagianni M, Galani IE, Koltsida O. Interferon-λs: Front-Line Guardians of Immunity and Homeostasis in the Respiratory Tract. Front Immunol. 2017 Sep;8:1232.
    1. Galani IE, Triantafyllia V, Eleminiadou EE, Koltsida O, Stavropoulos A, Manioudaki M, Thanos D, Doyle SE, Kotenko SV, Thanopoulou K, Andreakos E. Interferon-lambda Mediates Non-redundant Front-Line Antiviral Protection against Influenza Virus Infection without Compromising Host Fitness. Immunity. 2017;46:875–890. e876.
    1. Netea MG, Joosten LA, Latz E, Mills KH, Natoli G, Stunnenberg HG, et al. Trained immunity: A program of innate immune memory in health and disease. Science. 2016 Apr;352((6284)):aaf1098.
    1. Yao Y, Jeyanathan M, Haddadi S, Barra NG, Vaseghi-Shanjani M, Damjanovic D, et al. Induction of Autonomous Memory Alveolar Macrophages Requires T Cell Help and Is Critical to Trained Immunity. Cell. 2018 Nov;175((6)):1634–1650.e17.
    1. Netea MG, Joosten LA. Trained Immunity and Local Innate Immune Memory in the Lung. Cell. 2018 Nov;175((6)):1463–5.
    1. Te Velthuis AJ, Long JC, Bauer DL, Fan RL, Yen HL, Sharps J, et al. Mini viral RNAs act as innate immune agonists during influenza virus infection. Nat Microbiol. 2018 Nov;3((11)):1234–42.
    1. Berkhout B. RNAi-mediated antiviral immunity in mammals. Curr Opin Virol. 2018 Oct;32:9–14.
    1. Paludan SR. Innate Antiviral Defenses Independent of Inducible IFNα/β Production. Trends Immunol. 2016 Sep;37((9)):588–96.
    1. Cheng SC, Joosten LA, Netea MG. The interplay between central metabolism and innate immune responses. Cytokine Growth Factor Rev. 2014 Dec;25((6)):707–13.
    1. Cheng SC, Quintin J, Cramer RA, Shepardson KM, Saeed S, Kumar V, et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science. 2014 Sep;345((6204)):1250684.
    1. Kelly B, O'Neill LA. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res. 2015 Jul;25((7)):771–84.
    1. Romero-Brey I, Bartenschlager R. Membranous replication factories induced by plus-strand RNA viruses. Viruses. 2014 Jul;6((7)):2826–57.
    1. den Boon JA, Ahlquist P. Organelle-like membrane compartmentalization of positive-strand RNA virus replication factories. Annu Rev Microbiol. 2010;64((1)):241–56.
    1. van der Hoeven B, Oudshoorn D, Koster AJ, Snijder EJ, Kikkert M, Bárcena M. Biogenesis and architecture of arterivirus replication organelles. Virus Res. 2016 Jul;220:70–90.
    1. Lifland AW, Jung J, Alonas E, Zurla C, Crowe JE, Jr, Santangelo PJ. Human respiratory syncytial virus nucleoprotein and inclusion bodies antagonize the innate immune response mediated by MDA5 and MAVS. J Virol. 2012 Aug;86((15)):8245–58.
    1. Collins PL, Fearns R, Graham BS. Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease. Curr Top Microbiol Immunol. 2013;372:3–38.
    1. Oudshoorn D, Rijs K, Limpens RW, Groen K, Koster AJ, Snijder EJ, et al. Expression and Cleavage of Middle East Respiratory Syndrome Coronavirus nsp3-4 Polyprotein Induce the Formation of Double-Membrane Vesicles That Mimic Those Associated with Coronaviral RNA Replication. MBio. 2017 Nov;8((6)):8.
    1. García J, García-Barreno B, Vivo A, Melero JA. Cytoplasmic inclusions of respiratory syncytial virus-infected cells: formation of inclusion bodies in transfected cells that coexpress the nucleoprotein, the phosphoprotein, and the 22K protein. Virology. 1993 Jul;195((1)):243–7.
    1. Suhy DA, Giddings TH, Jr, Kirkegaard K. Remodeling the endoplasmic reticulum by poliovirus infection and by individual viral proteins: an autophagy-like origin for virus-induced vesicles. J Virol. 2000 Oct;74((19)):8953–65.
    1. Al-Mulla HM, Turrell L, Smith NM, Payne L, Baliji S, Züst R, et al. Competitive fitness in coronaviruses is not correlated with size or number of double-membrane vesicles under reduced-temperature growth conditions. MBio. 2014 Apr;5((2)):e01107–13.
    1. Oudshoorn D, van der Hoeven B, Limpens RW, Beugeling C, Snijder EJ, Bárcena M, et al. Antiviral Innate Immune Response Interferes with the Formation of Replication-Associated Membrane Structures Induced by a Positive-Strand RNA Virus. MBio. 2016 Dec;7((6)):7.
    1. Praefcke GJ. Regulation of innate immune functions by guanylate-binding proteins. Int J Med Microbiol. 2017
    1. Scutigliani EM, Kikkert M. Interaction of the innate immune system with positive-strand RNA virus replication organelles. Cytokine Growth F R
    1. Santos JC, Broz P. Sensing of invading pathogens by GBPs: at the crossroads between cell-autonomous and innate immunity. J Leukoc Biol. 2018 Oct;104((4)):729–35.
    1. Haller O, Staeheli P, Schwemmle M, Kochs G. Mx GTPases: dynamin-like antiviral machines of innate immunity. Trends Microbiol. 2015 Mar;23((3)):154–63.
    1. Biering SB, Choi J, Halstrom RA, Brown HM, Beatty WL, Lee S, McCune BT, Dominici E, Williams LE, Orchard RC, Wilen CB, Yamamoto M, Coers J, Taylor GA, Hwang S. Viral Replication Complexes Are Targeted by LC3-Guided Interferon-Inducible GTPases. Cell Host Microbe. 2017;22:74–85. e77.
    1. Choi J, Biering SB, Hwang S. Quo vadis? Interferon-inducible GTPases go to their target membranes via the LC3-conjugation system of autophagy. Small GTPases. 2017 Oct;8((4)):199–207.
    1. Liu G, Lu Y, Thulasi Raman SN, Xu F, Wu Q, Li Z, et al. Nuclear-resident RIG-I senses viral replication inducing antiviral immunity. Nat Commun. 2018 Aug;9((1)):3199.
    1. Pichlmair A, Schulz O, Tan CP, Näslund TI, Liljeström P, Weber F, et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science. 2006 Nov;314((5801)):997–1001.
    1. Rehwinkel J, Tan CP, Goubau D, Schulz O, Pichlmair A, Bier K, et al. RIG-I detects viral genomic RNA during negative-strand RNA virus infection. Cell. 2010 Feb;140((3)):397–408.
    1. Weber M, Sediri H, Felgenhauer U, Binzen I, Bänfer S, Jacob R, et al. Influenza virus adaptation PB2-627K modulates nucleocapsid inhibition by the pathogen sensor RIG-I. Cell Host Microbe. 2015 Mar;17((3)):309–19.
    1. Wu W, Zhang W, Duggan ES, Booth JL, Zou MH, Metcalf JP. RIG-I and TLR3 are both required for maximum interferon induction by influenza virus in human lung alveolar epithelial cells. Virology. 2015 Aug;482:181–8.
    1. Nordmann A, Wixler L, Boergeling Y, Wixler V, Ludwig S. A new splice variant of the human guanylate-binding protein 3 mediates anti-influenza activity through inhibition of viral transcription and replication. FASEB J. 2012 Mar;26((3)):1290–300.
    1. Flanegan JB, Petterson RF, Ambros V, Hewlett NJ, Baltimore D. Covalent linkage of a protein to a defined nucleotide sequence at the 5′-terminus of virion and replicative intermediate RNAs of poliovirus. Proc Natl Acad Sci USA. 1977 Mar;74((3)):961–5.
    1. Lee YF, Nomoto A, Detjen BM, Wimmer E. A protein covalently linked to poliovirus genome RNA. Proc Natl Acad Sci USA. 1977 Jan;74((1)):59–63.
    1. Pelletier J, Sonenberg N. Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature. 1988 Jul;334((6180)):320–5.
    1. Jang SK, Kräusslich HG, Nicklin MJ, Duke GM, Palmenberg AC, Wimmer E. A segment of the 5′ nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation. J Virol. 1988 Aug;62((8)):2636–43.
    1. De Vlugt C, Sikora D, Pelchat M. Insight into Influenza: A Virus Cap-Snatching. Viruses. 2018 Nov;10((11)):10.
    1. Barik S. The structure of the 5′ terminal cap of the respiratory syncytial virus mRNA. J Gen Virol. 1993 Mar;74((Pt 3)):485–90.
    1. Züst R, Cervantes-Barragan L, Habjan M, Maier R, Neuman BW, Ziebuhr J, et al. Ribose 2′-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat Immunol. 2011 Feb;12((2)):137–43.
    1. Menachery VD, Eisfeld AJ, Schäfer A, Josset L, Sims AC, Proll S, et al. Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses. MBio. 2014 May;5((3)):e01174–14.
    1. Kindler E, Gil-Cruz C, Spanier J, Li Y, Wilhelm J, Rabouw HH, et al. Early endonuclease-mediated evasion of RNA sensing ensures efficient coronavirus replication. PLoS Pathog. 2017 Feb;13((2)):e1006195.
    1. Deng X, Hackbart M, Mettelman RC, O'Brien A, Mielech AM, Yi G, et al. Coronavirus nonstructural protein 15 mediates evasion of dsRNA sensors and limits apoptosis in macrophages. Proc Natl Acad Sci USA. 2017 May;114((21)):E4251–60.
    1. Dias A, Bouvier D, Crépin T, McCarthy AA, Hart DJ, Baudin F, et al. The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature. 2009 Apr;458((7240)):914–8.
    1. Yuan P, Bartlam M, Lou Z, Chen S, Zhou J, He X, et al. Crystal structure of an avian influenza polymerase PA(N) reveals an endonuclease active site. Nature. 2009 Apr;458((7240)):909–13.
    1. Jagger BW, Wise HM, Kash JC, Walters KA, Wills NM, Xiao YL, et al. An overlapping protein-coding region in influenza A virus segment 3 modulates the host response. Science. 2012 Jul;337((6091)):199–204.
    1. Bavagnoli L, Cucuzza S, Campanini G, Rovida F, Paolucci S, Baldanti F, et al. The novel influenza A virus protein PA-X and its naturally deleted variant show different enzymatic properties in comparison to the viral endonuclease PA. Nucleic Acids Res. 2015 Oct;43((19)):9405–17.
    1. Hayashi T, MacDonald LA, Takimoto T, Influenza A. Influenza A Virus Protein PA-X Contributes to Viral Growth and Suppression of the Host Antiviral and Immune Responses. J Virol. 2015 Jun;89((12)):6442–52.
    1. Nogales A, Martinez-Sobrido L, Topham DJ, DeDiego ML. Modulation of Innate Immune Responses by the Influenza A NS1 and PA-X Proteins. Viruses. 2018 Dec;10((12)):10.
    1. Wang BX, Fish EN. Interactions Between NS1 of Influenza A Viruses and Interferon-α/β: Determinants for Vaccine Development. J Interferon Cytokine Res. 2017 Aug;37((8)):331–41.
    1. Krug RM. Functions of the influenza A virus NS1 protein in antiviral defense. Curr Opin Virol. 2015 Jun;12:1–6.
    1. Le Pen J, Jiang H, Di Domenico T, Kneuss E, Kosałka J, Leung C, et al. Terminal uridylyltransferases target RNA viruses as part of the innate immune system. Nat Struct Mol Biol. 2018 Sep;25((9)):778–86.
    1. Lim J, Ha M, Chang H, Kwon SC, Simanshu DK, Patel DJ, et al. Uridylation by TUT4 and TUT7 marks mRNA for degradation. Cell. 2014 Dec;159((6)):1365–76.
    1. Huo Y, Shen J, Wu H, Zhang C, Guo L, Yang J, et al. Widespread 3′-end uridylation in eukaryotic RNA viruses. Sci Rep. 2016 May;6((1)):25454.
    1. Lloyd JP. The evolution and diversity of the nonsense-mediated mRNA decay pathway. F1000 Res. 2018 Aug;7:1299.
    1. Wada M, Lokugamage KG, Nakagawa K, Narayanan K, Makino S. Interplay between coronavirus, a cytoplasmic RNA virus, and nonsense-mediated mRNA decay pathway. Proc Natl Acad Sci USA. 2018 Oct;115((43)):E10157–66.
    1. Levene RE, Gaglia MM. Host Shutoff in Influenza A Virus: Many Means to an End. Viruses. 2018 Sep;10((9)):10.
    1. Nemeroff ME, Barabino SM, Li Y, Keller W, Krug RM. Influenza virus NS1 protein interacts with the cellular 30 kDa subunit of CPSF and inhibits 3′end formation of cellular pre-mRNAs. Mol Cell. 1998 Jun;1((7)):991–1000.
    1. Tanaka T, Kamitani W, DeDiego ML, Enjuanes L, Matsuura Y. Severe acute respiratory syndrome coronavirus nsp1 facilitates efficient propagation in cells through a specific translational shutoff of host mRNA. J Virol. 2012 Oct;86((20)):11128–37.
    1. Lokugamage KG, Narayanan K, Huang C, Makino S. Severe acute respiratory syndrome coronavirus protein nsp1 is a novel eukaryotic translation inhibitor that represses multiple steps of translation initiation. J Virol. 2012 Dec;86((24)):13598–608.
    1. Huang C, Lokugamage KG, Rozovics JM, Narayanan K, Semler BL, Makino S. SARS coronavirus nsp1 protein induces template-dependent endonucleolytic cleavage of mRNAs: viral mRNAs are resistant to nsp1-induced RNA cleavage. PLoS Pathog. 2011 Dec;7((12)):e1002433.
    1. Kamitani W, Huang C, Narayanan K, Lokugamage KG, Makino S. A two-pronged strategy to suppress host protein synthesis by SARS coronavirus Nsp1 protein. Nat Struct Mol Biol. 2009 Nov;16((11)):1134–40.
    1. Lokugamage KG, Narayanan K, Nakagawa K, Terasaki K, Ramirez SI, Tseng CT, et al. Middle East Respiratory Syndrome Coronavirus nsp1 Inhibits Host Gene Expression by Selectively Targeting mRNAs Transcribed in the Nucleus while Sparing mRNAs of Cytoplasmic Origin. J Virol. 2015 Nov;89((21)):10970–81.
    1. Gaglia MM, Covarrubias S, Wong W, Glaunsinger BA. A common strategy for host RNA degradation by divergent viruses. J Virol. 2012 Sep;86((17)):9527–30.
    1. Lamphear BJ, Yan R, Yang F, Waters D, Liebig HD, Klump H, et al. Mapping the cleavage site in protein synthesis initiation factor eIF-4 gamma of the 2A proteases from human Coxsackievirus and rhinovirus. J Biol Chem. 1993 Sep;268((26)):19200–3.
    1. Petersen JF, Cherney MM, Liebig HD, Skern T, Kuechler E, James MN. The structure of the 2A proteinase from a common cold virus: a proteinase responsible for the shut-off of host-cell protein synthesis. EMBO J. 1999 Oct;18((20)):5463–75.
    1. Aumayr M, Schrempf A, Üzülmez Ö, Olek KM, Skern T. Interaction of 2A proteinase of human rhinovirus genetic group A with eIF4E is required for eIF4G cleavage during infection. Virology. 2017 Nov;511:123–34.
    1. Bruce SR, Atkins CL, Colasurdo GN, Alcorn JL. Respiratory syncytial virus infection alters surfactant protein A expression in human pulmonary epithelial cells by reducing translation efficiency. Am J Physiol Lung Cell Mol Physiol. 2009 Oct;297((4)):L559–67.
    1. Kim SS, Sze L, Lam KP. The stress granule protein G3BP1 binds viral dsRNA and RIG-I to enhance IFN-beta response. J Biol Chem. 2019
    1. McCormick C, Khaperskyy DA. Translation inhibition and stress granules in the antiviral immune response. Nat Rev Immunol. 2017 Oct;17((10)):647–60.
    1. Onomoto K, Jogi M, Yoo JS, Narita R, Morimoto S, Takemura A, et al. Critical role of an antiviral stress granule containing RIG-I and PKR in viral detection and innate immunity. PLoS One. 2012;7((8)):e43031.
    1. Sánchez-Aparicio MT, Ayllón J, Leo-Macias A, Wolff T, García-Sastre A. Subcellular Localizations of RIG-I, TRIM25, and MAVS Complexes. J Virol. 2017 Jan;91((2)):91.
    1. Oh SW, Onomoto K, Wakimoto M, Onoguchi K, Ishidate F, Fujiwara T, et al. Leader-Containing Uncapped Viral Transcript Activates RIG-I in Antiviral Stress Granules. PLoS Pathog. 2016 Feb;12((2)):e1005444.
    1. Lindquist ME, Lifland AW, Utley TJ, Santangelo PJ, Crowe JE., Jr Respiratory syncytial virus induces host RNA stress granules to facilitate viral replication. J Virol. 2010 Dec;84((23)):12274–84.
    1. Lindquist ME, Mainou BA, Dermody TS, Crowe JE., Jr Activation of protein kinase R is required for induction of stress granules by respiratory syncytial virus but dispensable for viral replication. Virology. 2011 Apr;413((1)):103–10.
    1. Cervantes-Ortiz SL, Zamorano Cuervo N, Grandvaux N. Respiratory Syncytial Virus and Cellular Stress Responses: Impact on Replication and Physiopathology. Viruses. 2016 May;8((5)):8.
    1. Rabouw HH, Langereis MA, Knaap RC, Dalebout TJ, Canton J, Sola I, et al. Middle East Respiratory Coronavirus Accessory Protein 4a Inhibits PKR-Mediated Antiviral Stress Responses. PLoS Pathog. 2016 Oct;12((10)):e1005982.
    1. Nakagawa K, Narayanan K, Wada M, Makino S. Inhibition of Stress Granule Formation by Middle East Respiratory Syndrome Coronavirus 4a Accessory Protein Facilitates Viral Translation, Leading to Efficient Virus Replication. J Virol. 2018 Sep;92((20)):92.
    1. Slaine PD, Kleer M, Smith NK, Khaperskyy DA, McCormick C. Stress Granule-Inducing Eukaryotic Translation Initiation Factor 4A Inhibitors Block Influenza A Virus Replication. Viruses. 2017 Dec;9((12)):9.
    1. Khaperskyy DA, Emara MM, Johnston BP, Anderson P, Hatchette TF, McCormick C. Influenza a virus host shutoff disables antiviral stress-induced translation arrest. PLoS Pathog. 2014 Jul;10((7)):e1004217.
    1. Khaperskyy DA, Hatchette TF, McCormick C. Influenza A virus inhibits cytoplasmic stress granule formation. FASEB J. 2012 Apr;26((4)):1629–39.
    1. Li T, Li X, Zhu W, Wang H, Mei L, Wu S, et al. NF90 is a novel influenza A virus NS1-interacting protein that antagonizes the inhibitory role of NS1 on PKR phosphorylation. FEBS Lett. 2016 Aug;590((16)):2797–810.
    1. Visser LJ, Medina GN, Rabouw HH, de Groot RJ, Langereis MA, de Los Santos T, et al. Foot-and-Mouth Disease Virus Leader Protease Cleaves G3BP1 and G3BP2 and Inhibits Stress Granule Formation. J Virol. 2019 Jan;93((2)):93.
    1. Yang X, Hu Z, Fan S, Zhang Q, Zhong Y, Guo D, et al. Picornavirus 2A protease regulates stress granule formation to facilitate viral translation. PLoS Pathog. 2018 Feb;14((2)):e1006901.
    1. Feng Q, Langereis MA, van Kuppeveld FJ. Induction and suppression of innate antiviral responses by picornaviruses. Cytokine Growth Factor Rev. 2014 Oct;25((5)):577–85.
    1. White JP, Cardenas AM, Marissen WE, Lloyd RE. Inhibition of cytoplasmic mRNA stress granule formation by a viral proteinase. Cell Host Microbe. 2007 Nov;2((5)):295–305.
    1. Yang X, Hu Z, Zhang Q, Fan S, Zhong Y, Guo D, et al. SG formation relies on eIF4GI-G3BP interaction which is targeted by picornavirus stress antagonists. Cell Discov. 2019 Jan;5((1)):1.
    1. Watters K, Palmenberg AC. Differential processing of nuclear pore complex proteins by rhinovirus 2A proteases from different species and serotypes. J Virol. 2011 Oct;85((20)):10874–83.
    1. Walker EJ, Younessi P, Fulcher AJ, McCuaig R, Thomas BJ, Bardin PG, et al. Rhinovirus 3C protease facilitates specific nucleoporin cleavage and mislocalisation of nuclear proteins in infected host cells. PLoS One. 2013 Aug;8((8)):e71316.
    1. Walker E, Jensen L, Croft S, Wei K, Fulcher AJ, Jans DA, et al. Rhinovirus 16 2A Protease Affects Nuclear Localization of 3CD during Infection. J Virol. 2016 Nov;90((24)):11032–42.
    1. Ghildyal R, Jordan B, Li D, Dagher H, Bardin PG, Gern JE, et al. Rhinovirus 3C protease can localize in the nucleus and alter active and passive nucleocytoplasmic transport. J Virol. 2009 Jul;83((14)):7349–52.
    1. Amineva SP, Aminev AG, Palmenberg AC, Gern JE. Rhinovirus 3C protease precursors 3CD and 3CD' localize to the nuclei of infected cells. J Gen Virol. 2004 Oct;85((Pt 10)):2969–79.
    1. Drahos J, Racaniello VR. Cleavage of IPS-1 in cells infected with human rhinovirus. J Virol. 2009 Nov;83((22)):11581–7.
    1. Lötzerich M, Roulin PS, Boucke K, Witte R, Georgiev O, Greber UF. Rhinovirus 3C protease suppresses apoptosis and triggers caspase-independent cell death. Cell Death Dis. 2018 Feb;9((3)):272.
    1. Croft SN, Walker EJ, Ghildyal R. Human Rhinovirus 3C protease cleaves RIPK1, concurrent with caspase 8 activation. Sci Rep. 2018 Jan;8((1)):1569.
    1. Zhu X, Fang L, Wang D, Yang Y, Chen J, Ye X, et al. Porcine deltacoronavirus nsp5 inhibits interferon-β production through the cleavage of NEMO. Virology. 2017 Feb;502:33–8.
    1. Wang D, Fang L, Shi Y, Zhang H, Gao L, Peng G, et al. Porcine Epidemic Diarrhea Virus 3C-Like Protease Regulates Its Interferon Antagonism by Cleaving NEMO. J Virol. 2015 Dec;90((4)):2090–101.
    1. Heaton SM, Borg NA, Dixit VM. Ubiquitin in the activation and attenuation of innate antiviral immunity. J Exp Med. 2016 Jan;213((1)):1–13.
    1. Sulea T, Lindner HA, Purisima EO, Ménard R. Deubiquitination, a new function of the severe acute respiratory syndrome coronavirus papain-like protease? J Virol. 2005 Apr;79((7)):4550–1.
    1. Mielech AM, Chen Y, Mesecar AD, Baker SC. Nidovirus papain-like proteases: multifunctional enzymes with protease, deubiquitinating and deISGylating activities. Virus Res. 2014 Dec;194:184–90.
    1. Yuan L, Chen Z, Song S, Wang S, Tian C, Xing G, et al. p53 degradation by a coronavirus papain-like protease suppresses type I interferon signaling. J Biol Chem. 2015 Jan;290((5)):3172–82.
    1. Ma-Lauer Y, Carbajo-Lozoya J, Hein MY, Müller MA, Deng W, Lei J, et al. p53 down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PLpro via E3 ubiquitin ligase RCHY1. Proc Natl Acad Sci USA. 2016 Aug;113((35)):E5192–201.
    1. Rudnicka A, Yamauchi Y. Ubiquitin in Influenza Virus Entry and Innate Immunity. Viruses. 2016 Oct;8((10)):8.
    1. Gack MU, Albrecht RA, Urano T, Inn KS, Huang IC, Carnero E, et al. Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe. 2009 May;5((5)):439–49.
    1. Okamoto M, Kouwaki T, Fukushima Y, Oshiumi H. Regulation of RIG-I Activation by K63-Linked Polyubiquitination. Front Immunol. 2018 Jan;8:1942.
    1. Versteeg GA, Hale BG, van Boheemen S, Wolff T, Lenschow DJ, García-Sastre A. Species-specific antagonism of host ISGylation by the influenza B virus NS1 protein. J Virol. 2010 May;84((10)):5423–30.
    1. Pizzorno A, Dubois J, Machado D, Cartet G, Traversier A, Julien T, et al. Influenza A viruses alter the stability and antiviral contribution of host E3-ubiquitin ligase Mdm2 during the time-course of infection. Sci Rep. 2018 Feb;8((1)):3746.
    1. Feng W, Sun X, Shi N, Zhang M, Guan Z, Duan M. Influenza a virus NS1 protein induced A20 contributes to viral replication by suppressing interferon-induced antiviral response. Biochem Biophys Res Commun. 2017 Jan;482((4)):1107–13.
    1. Ban J, Lee NR, Lee NJ, Lee JK, Quan FS, Inn KS. Human Respiratory Syncytial Virus NS 1 Targets TRIM25 to Suppress RIG-I Ubiquitination and Subsequent RIG-I-Mediated Antiviral Signaling. Viruses. 2018 Dec;10((12)):10.
    1. Ramaswamy M, Shi L, Monick MM, Hunninghake GW, Look DC. Specific inhibition of type I interferon signal transduction by respiratory syncytial virus. Am J Respir Cell Mol Biol. 2004 Jun;30((6)):893–900.
    1. Ramaswamy M, Shi L, Varga SM, Barik S, Behlke MA, Look DC. Respiratory syncytial virus nonstructural protein 2 specifically inhibits type I interferon signal transduction. Virology. 2006 Jan;344((2)):328–39.
    1. Whelan JN, Tran KC, van Rossum DB, Teng MN. Identification of Respiratory Syncytial Virus Nonstructural Protein 2 Residues Essential for Exploitation of the Host Ubiquitin System and Inhibition of Innate Immune Responses. J Virol. 2016 Jun;90((14)):6453–63.
    1. González-Sanz R, Mata M, Bermejo-Martín J, Álvarez A, Cortijo J, Melero JA, et al. ISG15 Is Upregulated in Respiratory Syncytial Virus Infection and Reduces Virus Growth through Protein ISGylation. J Virol. 2016 Jan;90((7)):3428–38.
    1. Wang D, Fang L, Li P, Sun L, Fan J, Zhang Q, et al. The leader proteinase of foot-and-mouth disease virus negatively regulates the type I interferon pathway by acting as a viral deubiquitinase. J Virol. 2011 Apr;85((8)):3758–66.
    1. Fehr AR, Jankevicius G, Ahel I, Perlman S. Viral Macrodomains: Unique Mediators of Viral Replication and Pathogenesis. Trends Microbiol. 2018 Jul;26((7)):598–610.
    1. Shokri S, Mahmoudvand S, Taherkhani R, Farshadpour F. Modulation of the immune response by Middle East respiratory syndrome coronavirus. J Cell Physiol. 2018
    1. Schulz KS, Mossman KL. Viral Evasion Strategies in Type I IFN Signaling - A Summary of Recent Developments. Front Immunol. 2016 Nov;7:498.
    1. Lei X, Xiao X, Wang J. Innate Immunity Evasion by Enteroviruses: Insights into Virus-Host Interaction. Viruses. 2016 Jan;8((1)):8.
    1. Chatterjee S, Basler CF, Amarasinghe GK, Leung DW. Molecular Mechanisms of Innate Immune Inhibition by Non-Segmented Negative-Sense RNA Viruses. J Mol Biol. 2016 Aug;428((17)):3467–82.
    1. Ma DY, Suthar MS. Mechanisms of innate immune evasion in re-emerging RNA viruses. Curr Opin Virol. 2015 Jun;12:26–37.
    1. Gralinski LE, Baric RS. Molecular pathology of emerging coronavirus infections. J Pathol. 2015 Jan;235((2)):185–95.
    1. Guo H, Kumar P, Malarkannan S. Evasion of natural killer cells by influenza virus. J Leukoc Biol. 2011 Feb;89((2)):189–94.
    1. Hale BG, Albrecht RA, García-Sastre A. Innate immune evasion strategies of influenza viruses. Future Microbiol. 2010 Jan;5((1)):23–41.
    1. Weber M, Weber F. Segmented negative-strand RNA viruses and RIG-I: divide (your genome) and rule. Curr Opin Microbiol. 2014 Aug;20:96–102.
    1. Onomoto K, Yoneyama M, Fung G, Kato H, Fujita T. Antiviral innate immunity and stress granule responses. Trends Immunol. 2014 Sep;35((9)):420–8.
    1. Menachery VD, Debbink K, Baric RS. Coronavirus non-structural protein 16: evasion, attenuation, and possible treatments. Virus Res. 2014 Dec;194:191–9.
    1. Marc D. Influenza virus non-structural protein NS1: interferon antagonism and beyond. J Gen Virol. 2014 Dec;95((Pt 12)):2594–611.
    1. DeDiego ML, Nieto-Torres JL, Jimenez-Guardeño JM, Regla-Nava JA, Castaño-Rodriguez C, Fernandez-Delgado R, et al. Coronavirus virulence genes with main focus on SARS-CoV envelope gene. Virus Res. 2014 Dec;194:124–37.
    1. Nicholls JM. The battle between influenza and the innate immune response in the human respiratory tract. Infect Chemother. 2013 Mar;45((1)):11–21.
    1. Harris KG, Coyne CB. Enter at your own risk: how enteroviruses navigate the dangerous world of pattern recognition receptor signaling. Cytokine. 2013 Sep;63((3)):230–6.
    1. van de Sandt CE, Kreijtz JH, Rimmelzwaan GF. Evasion of influenza A viruses from innate and adaptive immune responses. Viruses. 2012 Sep;4((9)):1438–76.
    1. Oshiumi H, Matsumoto M, Seya T. Ubiquitin-mediated modulation of the cytoplasmic viral RNA sensor RIG-I. J Biochem. 2012 Jan;151((1)):5–11.
    1. Munir M. TRIM proteins: another class of viral victims. Sci Signal. 2010 Apr;3((118)):jc2.
    1. Fleming SB. Viral Inhibition of the IFN-Induced JAK/STAT Signalling Pathway: Development of Live Attenuated Vaccines by Mutation of Viral-Encoded IFN-Antagonists. Vaccines (Basel) 2016 Jun;4((3)):4.
    1. Chan YK, Gack MU. Viral evasion of intracellular DNA and RNA sensing. Nat Rev Microbiol. 2016 Jun;14((6)):360–73.
    1. Rossi GA, Silvestri M, Colin AA. Respiratory syncytial virus infection of airway cells: role of microRNAs. Pediatr Pulmonol. 2015 Jul;50((7)):727–32.
    1. Narayanan K, Ramirez SI, Lokugamage KG, Makino S. Coronavirus nonstructural protein 1: common and distinct functions in the regulation of host and viral gene expression. Virus Res. 2015 Apr;202:89–100.
    1. Goraya MU, Wang S, Munir M, Chen JL. Induction of innate immunity and its perturbation by influenza viruses. Protein Cell. 2015 Oct;6((10)):712–21.
    1. Dash P, Thomas PG. Host detection and the stealthy phenotype in influenza virus infection. Curr Top Microbiol Immunol. 2015;386:121–47.
    1. Báez-Santos YM, St John SE, Mesecar AD. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral Res. 2015 Mar;115:21–38.
    1. Balistreri G, Bognanni C, Mühlemann O. Virus Escape and Manipulation of Cellular Nonsense-Mediated mRNA Decay. Viruses. 2017 Jan;9((1)):9.
    1. Agrawal P, Nawadkar R, Ojha H, Kumar J, Sahu A. Complement Evasion Strategies of Viruses: an Overview. Front Microbiol. 2017 Jun;8:1117.
    1. Wong LY, Lui PY, Jin DY. A molecular arms race between host innate antiviral response and emerging human coronaviruses. Virol Sin. 2016 Feb;31((1)):12–23.
    1. Weber-Gerlach M, Weber F. To Conquer the Host, Influenza Virus Is Packing It In: Interferon-Antagonistic Strategies beyond NS1. J Virol. 2016 Sep;90((19)):8389–94.
    1. Liu Y, Olagnier D, Lin R. Host and Viral Modulation of RIG-I-Mediated Antiviral Immunity. Front Immunol. 2017 Jan;7:662.
    1. Kindler E, Thiel V, Weber F. Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response. Adv Virus Res. 2016;96:219–43.
    1. Unterholzner L, Almine JF. Camouflage and interception: how pathogens evade detection by intracellular nucleic acid sensors. Immunology. 2019 Mar;156((3)):217–27.
    1. Lei J, Kusov Y, Hilgenfeld R. Nsp3 of coronaviruses: structures and functions of a large multi-domain protein. Antiviral Res. 2018 Jan;149:58–74.
    1. Ascough S, Paterson S, Chiu C. Induction and Subversion of Human Protective Immunity: Contrasting Influenza and Respiratory Syncytial Virus. Front Immunol. 2018 Mar;9:323.
    1. Sun Y, López CB. The innate immune response to RSV: advances in our understanding of critical viral and host factors. Vaccine. 2017 Jan;35((3)):481–8.
    1. Rodríguez Pulido M, Sáiz M. Molecular Mechanisms of Foot-and-Mouth Disease Virus Targeting the Host Antiviral Response. Front Cell Infect Microbiol. 2017 Jun;7:252.
    1. Plant EP, Ilyushina NA, Sheikh F, Donnelly RP, Ye Z. Influenza virus NS1 protein mutations at position 171 impact innate interferon responses by respiratory epithelial cells. Virus Res. 2017 Aug;240:81–6.
    1. Canedo-Marroquín G, Acevedo-Acevedo O, Rey-Jurado E, Saavedra JM, Lay MK, Bueno SM, et al. Modulation of Host Immunity by Human Respiratory Syncytial Virus Virulence Factors: A Synergic Inhibition of Both Innate and Adaptive Immunity. Front Cell Infect Microbiol. 2017 Aug;7:367.
    1. Wimmer P, Schreiner S. Viral Mimicry to Usurp Ubiquitin and SUMO Host Pathways. Viruses. 2015 Aug;7((9)):4854–72.
    1. van der Hoek L. Human coronaviruses: what do they cause? Antivir Ther. 2007;12(4 Pt B):651–8.
    1. Collins PL, Melero JA. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res. 2011 Dec;162((1-2)):80–99.
    1. Farrag MA, Almajhdi FN. Human Respiratory Syncytial Virus: Role of Innate Immunity in Clearance and Disease Progression. Viral Immunol. 2016 Jan-Feb;29((1)):11–26.
    1. Bohmwald K, Espinoza JA, Becerra D, Rivera K, Lay MK, Bueno SM, et al. Inflammatory damage on respiratory and nervous systems due to hRSV infection. Curr Opin Immunol. 2015 Oct;36:14–21.
    1. Grainge CL, Davies DE. Epithelial injury and repair in airways diseases. Chest. 2013 Dec;144((6)):1906–12.
    1. Vandini S, Calamelli E, Faldella G, Lanari M. Immune and inflammatory response in bronchiolitis due to respiratory Syncytial Virus and Rhinovirus infections in infants. Paediatr Respir Rev. 2017 Sep;24:60–4.
    1. Newton AH, Cardani A, Braciale TJ. The host immune response in respiratory virus infection: balancing virus clearance and immunopathology. Semin Immunopathol. 2016 Jul;38((4)):471–82.
    1. Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PA, Bartlett NW, et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med. 2006 Sep;12((9)):1023–6.
    1. Wark PA, Johnston SL, Bucchieri F, Powell R, Puddicombe S, Laza-Stanca V, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med. 2005 Mar;201((6)):937–47.
    1. Contoli M, Ito K, Padovani A, Poletti D, Marku B, Edwards MR, et al. Th2 cytokines impair innate immune responses to rhinovirus in respiratory epithelial cells. Allergy. 2015 Aug;70((8)):910–20.
    1. Durrani SR, Montville DJ, Pratt AS, Sahu S, DeVries MK, Rajamanickam V, et al. Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children. J Allergy Clin Immunol. 2012 Aug;130((2)):489–95.
    1. Tay H, Wark PA, Bartlett NW. Advances in the treatment of virus-induced asthma. Expert Rev Respir Med. 2016 Jun;10((6)):629–41.
    1. Glanville N, Johnston SL. Challenges in developing a cross-serotype rhinovirus vaccine. Curr Opin Virol. 2015 Apr;11:83–8.
    1. Smith SB, Dampier W, Tozeren A, Brown JR, Magid-Slav M. Identification of common biological pathways and drug targets across multiple respiratory viruses based on human host gene expression analysis. PLoS One. 2012;7((3)):e33174.
    1. Pichlmair A, Kandasamy K, Alvisi G, Mulhern O, Sacco R, Habjan M, et al. Viral immune modulators perturb the human molecular network by common and unique strategies. Nature. 2012 Jul;487((7408)):486–90.
    1. Schindewolf C, Menachery VD. Middle East Respiratory Syndrome Vaccine Candidates: cautious Optimism. Viruses. 2019 Jan;11((1)):11.
    1. Hsu AC. Influenza Virus: A Master Tactician in Innate Immune Evasion and Novel Therapeutic Interventions. Front Immunol. 2018 Apr;9:743.
    1. Bailey-Elkin BA, Knaap RC, Johnson GG, Dalebout TJ, Ninaber DK, van Kasteren PB, et al. Crystal structure of the Middle East respiratory syndrome coronavirus (MERS-CoV) papain-like protease bound to ubiquitin facilitates targeted disruption of deubiquitinating activity to demonstrate its role in innate immune suppression. J Biol Chem. 2014 Dec;289((50)):34667–82.
    1. Zhang W, Bailey-Elkin BA, Knaap RC, Khare B, Dalebout TJ, Johnson GG, et al. Potent and selective inhibition of pathogenic viruses by engineered ubiquitin variants. PLoS Pathog. 2017 May;13((5)):e1006372.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner